BIOENGINEER

CD4 T Cell Help Powers Immunotherapy Response in Tumors Lacking MHC-I

Mouse experiments show that CD4+ T cells license CD8+ T cells through CD40 signaling, enabling combination immunotherapy to ...
BIOENGINEER

Endothelial ICAM-1 Polarization Traps T Cells at Melanoma Tumor Edges

Endothelial ICAM-1 becomes polarized to the tumor periphery as melanomas grow, trapping T cells at the margins, and blocking ...
ascopubs.org

DNA Damage Response Alterations and Immune Checkpoint Blockade Outcomes Across Multiple Cancers

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I We integrated ...
BioWorld

SU-056 is a potent antitumor and immunomodulatory agent in osteosarcoma

Researchers from Oregon Health & Science University investigated the potential of SU-056, a small-molecule Y-box binding protein 1 (YB-1) inhibitor, to directly suppress osteosarcoma and improve ...
ascopubs.org

Real-world outcomes of dual checkpoint blockade versus PD-1/VEGF inhibitor combination as first-line therapy in metastatic renal cell carcinoma.

Single-agent versus combination paradigms: A systematic review and meta-analysis of the immunotherapy clinical profile in metastatic renal cell carcinoma. This is an ASCO Meeting Abstract from the ...